Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Helsinn Group Stories

2014-03-13 08:29:55

BRIDGEWATER, New Jersey, March 13, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as one of the 100 best places to work in New Jersey in a survey and award program conducted by NJBIZ which recognizes and honors the state's top employers who show a dedication to their employees' growth and quality of life. In 2009 Helsinn...

2013-12-19 04:20:55

LUGANO, Switzerland, December 19, 2013 /PRNewswire/ -- The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination (NEPA), a Helsinn product under...

2013-12-09 12:25:55

Seeking indication for prevention of chemotherapy-induced nausea and vomiting LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Dec. 9, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) for prevention of acute and delayed...

2013-12-04 08:29:53

WOODCLIFF LAKE, N.J., Dec. 4, 2013 /PRNewswire/ -- Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer Symposium. The meeting will be held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the...

2013-12-03 04:24:19

LUGANO, Switzerland and BEIJING, December 3, 2013 /PRNewswire/ -- Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States, Helsinn is currently a worldwide leader in cancer supportive care,...

2013-11-12 00:21:56

LUGANO, Switzerland, November 12, 2013 /PRNewswire/ -- Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their...

2013-10-01 12:29:36

LUGANO, Switzerland, October 1, 2013 /PRNewswire/ -- The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi(R) (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The establishment of this...

2013-05-16 04:23:41

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...

2013-01-29 08:30:26

LUGANO, Switzerland and MEXICO CITY, January 29, 2013 /PRNewswire/ -- Swiss pharmaceutical Helsinn Group has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Peru, Ecuador and most of Central American countries, to this novel ghrelin receptor agonist. Anamorelin is a new first-in-class, once daily drug being developed for the treatment of cachexia-anorexia in NSCLC, a serious multifactorial...

2013-01-07 08:29:01

LUGANO, Switzerland, January 7, 2013 /PRNewswire/ -- Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be shared with an audience of institutional investors,...